Project Grant R56HL166263
Award Date
9/24/23
Completion Date
8/31/24
Dollars Obligated
$834K
Federal Agency
National Heart Lung and Blood Institute
Federal Grant Program
93.837
Assistance Type
Project Grant
Place of Performance
Boston, MA 02115, USA
Similar Awards
This Project Grant award of $601,563 was provided by the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research federal grant program (CFDA 93.837), with a project period from September 1, 2024 to August 31, 2027. The award supports research to investigate the pathogenic roles and molecular mechanisms of the histone lysine demethylases KDM5A and KDM5B in the development and progression of heart failure, with a focus on hereditary cardiomyopathies like Lamin...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $213,314 to The University of Iowa to investigate the molecular mechanisms underlying aldosterone-mediated sodium appetite. The research aims to: 1) determine the importance of aldosterone/mineralocorticoid receptor signaling in specific neurons for sodium appetite, 2) identify aldosterone-regulated genes in these neurons that could...
This Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) supports research into the role of the long non-coding RNA SALTE1 in vascular aging and heart failure with preserved ejection fraction (HFPEF). The $708,266 award to The General Hospital Corporation (doing business as Massachusetts General Hospital) will fund a 4-year research project to determine the role of SALTE1 in vascular aging and HFPEF, and examine the underlying...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) will provide $171,450.00 to investigate the biological mechanisms linking excess body fat (adiposity) and elevated blood lipid levels, and their combined impact on cardiovascular disease risk. The research, led by Dr. Dron, a computational geneticist, aims to: 1) measure how adiposity interacts with genetic variants to influence lipid levels, 2)...
This Project Grant award from the National Heart Lung and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) provides $190,491 to Beth Israel Deaconess Medical Center, Inc. to conduct research on plasma protein markers of the blood pressure response during exercise and their relation to incident hypertension and cardiovascular disease. The project aims to identify circulating proteins associated with exercise blood pressure that could serve as predictive markers for future...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research (CFDA 93.837) program, provides $1,135,350 to the Regents of the University of Michigan to conduct research on the genetic causes of primary aldosteronism (PA) in Black Americans. The key objectives are: 1) to define the spectrum of aldosterone-driver PA somatic mutations in Black American patients, and 2) to identify targeted therapeutics that block mutation-driven...
The National Heart, Lung, and Blood Institute (NHLBI), a division of the National Institutes of Health (NIH), awarded a $874,792 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to Vanderbilt University Medical Center (VUMC). The award, effective July 15, 2024 through June 30, 2028, will support research to: (1) identify new genetic variants associated with residual atherosclerotic cardiovascular disease (ASCVD) risk in patients on treatment to lower LDL-cholesterol...
This $2,559,308 Project Grant was awarded on January 14, 2025 by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research federal grant program (CFDA 93.837). The grant supports a study examining the impact of severe pre-eclampsia on heart function in a racially diverse cohort of women during and after pregnancy. The study aims to characterize the cardiomyopathic genetic profile of participants and assess the functional impact of specific genetic...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $699,133 in funding to the University of California, Los Angeles (UCLA) to conduct research on the epigenetic regulation of heart failure with preserved ejection fraction (HFPEF). The key goals are to reveal molecular insights into the actions of SGLT2 inhibitor and GLP1 agonist drugs across multiple organs, identify novel...
This federal Project Grant award under the National Heart Lung and Blood Institute's (NHLBI) Cardiovascular Diseases Research program (CFDA 93.837) provides $138,523 to Brigham & Women's Hospital Inc. to systematically compare the mechanisms involved in medial and intimal calcification subtypes, which are distinct drivers of age-related vascular disease and cardiovascular morbidity and mortality. The award, effective from July 2025 through May 2027, will use spatial and extracellular vesicle...